Given the importance of EGFR signaling as a therapeutic target in lung cancer [79,80], further examination of the effect of EGF, heregulin, and amphiregulin on GPER expression and function in lung cancer may provide new insights into resistance to EGFR inhibitors and or how estrogens stimulate lung cancer. This evidence concerns the gene EGFR and lung carcinoma.